The therapeutic antibodies developer has closed its series A round backed by GlaxoSmithKline.
US-based biotechnology company Atreca secured $56m in series A capital yesterday in a round featuring pharmaceutical firm GlaxoSmithKline.
The round was led by an unnamed healthcare fund and also featured the Bill and Melinda Gates Foundation and Mission Bay Capital.
The round included a conversion of debt financing into series A shares by some investors. Although Atreca has not named these investors, the Gates Foundation obtained an unsecured convertible note in 2012.
Atreca’s platform analyses immune responses to a disease…
